NO20053341L - Hindring og behandling av Alzheimers sykdom. - Google Patents

Hindring og behandling av Alzheimers sykdom.

Info

Publication number
NO20053341L
NO20053341L NO20053341A NO20053341A NO20053341L NO 20053341 L NO20053341 L NO 20053341L NO 20053341 A NO20053341 A NO 20053341A NO 20053341 A NO20053341 A NO 20053341A NO 20053341 L NO20053341 L NO 20053341L
Authority
NO
Norway
Prior art keywords
alzheimer
disease
prevention
inhibitor
treatment
Prior art date
Application number
NO20053341A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053341D0 (no
Inventor
Hubert Heuer
Laurent Pradier
Hans-Ludwig Schaefer
Thierry Canton
Jesus Benavides
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20053341D0 publication Critical patent/NO20053341D0/no
Publication of NO20053341L publication Critical patent/NO20053341L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO20053341A 2002-12-12 2005-07-08 Hindring og behandling av Alzheimers sykdom. NO20053341L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
NO20053341D0 NO20053341D0 (no) 2005-07-08
NO20053341L true NO20053341L (no) 2005-09-07

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053341A NO20053341L (no) 2002-12-12 2005-07-08 Hindring og behandling av Alzheimers sykdom.

Country Status (22)

Country Link
EP (1) EP1572174A1 (pl)
JP (1) JP2006514063A (pl)
KR (1) KR20050084250A (pl)
CN (1) CN1726016A (pl)
AR (1) AR042354A1 (pl)
AU (1) AU2003296802A1 (pl)
BR (1) BR0317280A (pl)
CA (1) CA2507945A1 (pl)
CO (1) CO5700712A2 (pl)
FR (1) FR2848452B1 (pl)
HR (1) HRP20050534A2 (pl)
MA (1) MA27500A1 (pl)
MX (1) MXPA05005556A (pl)
NO (1) NO20053341L (pl)
NZ (1) NZ540496A (pl)
PE (1) PE20040770A1 (pl)
PL (1) PL377110A1 (pl)
RS (1) RS20050420A (pl)
RU (1) RU2005121909A (pl)
TW (1) TW200503707A (pl)
WO (1) WO2004062652A1 (pl)
ZA (1) ZA200504656B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
MX2009012583A (es) * 2007-05-22 2010-03-08 Otsuka Pharma Co Ltd Un medicamento que comprende un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer.
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) * 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
EP0572560B1 (en) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
FR2848452A1 (fr) 2004-06-18
JP2006514063A (ja) 2006-04-27
PL377110A1 (pl) 2006-01-23
HRP20050534A2 (en) 2006-11-30
TW200503707A (en) 2005-02-01
NO20053341D0 (no) 2005-07-08
ZA200504656B (en) 2006-08-30
RU2005121909A (ru) 2006-01-20
FR2848452B1 (fr) 2007-04-06
MA27500A1 (fr) 2005-08-01
NZ540496A (en) 2008-04-30
WO2004062652A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
CA2507945A1 (fr) 2004-07-29
CN1726016A (zh) 2006-01-25
AR042354A1 (es) 2005-06-15
RS20050420A (sr) 2007-04-10
BR0317280A (pt) 2005-11-08
AU2003296802A1 (en) 2004-08-10
KR20050084250A (ko) 2005-08-26
PE20040770A1 (es) 2004-12-10
EP1572174A1 (fr) 2005-09-14
MXPA05005556A (es) 2005-07-26

Similar Documents

Publication Publication Date Title
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20034590D0 (no) Fremgangsmåter for behandling av vaskul¶r sykdom
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO20050607L (no) Fremgangsmate og innretning for tildeling av CO
NO20084362L (no) Difenylazetidinon derivater inneholdende kolesterol absorbsjonsinhibitor aktivitet
IS8071A (is) Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
WO2004010937A3 (en) Method of treating cancer
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
EA200400881A1 (ru) Азаарилпиперазины
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
WO2009027703A3 (en) Identifying organ damage
AR042354A1 (es) Aplicacion de inhibidores de recaptura intestinal del acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
NO20033228L (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forhindring av hjertesykdom
NO20061744L (no) Terapeutisk behandling
TW200635900A (en) Chemical compound and its use
NO20051664L (no) Behandling av demens og Parkinsons sykdom
WO2004087905A3 (en) Protein tyrosine phosphatase and inhibitors thereof
AU2003205174A1 (en) Molecules for disease detection and treatment

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application